06:30 EST Johnson & Johnson to acquire Intra-Cellular (ITCI) for $132.00 per share in cash
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Illumina launches pilot proteomics program with UK Biobank, collaborators
- Johnson & Johnson exploring bid for Intra-Cellular Therapies, Bloomberg reports
- Boston Scientific upgraded to Buy from Hold at Deutsche Bank
- Needham medtech & diagnostics analyst holds analyst/industry conference call
- Johnson & Johnson reports nipocalimab granted FDA Priority Review